Integra LifeSciences Holdings Corporation (IART)
IART Stock Price Chart
Explore Integra LifeSciences Holdings Corporation interactive price chart. Choose custom timeframes to analyze IART price movements and trends.
IART Company Profile
Discover essential business fundamentals and corporate details for Integra LifeSciences Holdings Corporation (IART) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
16 Aug 1995
Employees
4.40k
Website
https://www.integralife.comCEO
Mojdeh Poul
Description
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
IART Financial Timeline
Browse a chronological timeline of Integra LifeSciences Holdings Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is $0.48, while revenue estimate is $417.62m.
Earnings released on 5 May 2026
EPS came in at $0.54 surpassing the estimated $0.41 by +31.71%, while revenue for the quarter reached $391.92m , beating expectations by +2.65%.
Earnings released on 26 Feb 2026
EPS came in at $0.83 surpassing the estimated $0.79 by +5.06%, while revenue for the quarter reached $434.93m , beating expectations by +1.23%.
Earnings released on 30 Oct 2025
EPS came in at $0.54 surpassing the estimated $0.43 by +25.58%, while revenue for the quarter reached $402.06m , missing expectations by -6.41%.
Earnings released on 31 Jul 2025
EPS came in at $0.45 surpassing the estimated $0.43 by +4.65%, while revenue for the quarter reached $415.61m , beating expectations by +0.31%.
Earnings released on 5 May 2025
EPS came in at $0.41 falling short of the estimated $0.43 by -4.65%, while revenue for the quarter reached $382.65m , missing expectations by -4.95%.
Earnings released on 25 Feb 2025
EPS came in at $0.97 surpassing the estimated $0.86 by +12.79%, while revenue for the quarter reached $442.65m , beating expectations by +7.51%.
Earnings released on 4 Nov 2024
EPS came in at $0.41 surpassing the estimated $0.39 by +5.13%, while revenue for the quarter reached $380.83m , missing expectations by -14.51%.
Earnings released on 29 Jul 2024
EPS came in at $0.63 surpassing the estimated $0.62 by +1.61%, while revenue for the quarter reached $418.18m , beating expectations by +1.22%.
Earnings released on 6 May 2024
EPS came in at $0.55 matching the estimated $0.55, while revenue for the quarter reached $368.87m , beating expectations by +1.91%.
Earnings released on 28 Feb 2024
EPS came in at $0.89 falling short of the estimated $0.90 by -1.11%, while revenue for the quarter reached $397.04m , missing expectations by -0.58%.
Earnings released on 25 Oct 2023
EPS came in at $0.76 falling short of the estimated $0.78 by -2.56%, while revenue for the quarter reached $382.42m , missing expectations by -1.21%.
Earnings released on 26 Jul 2023
EPS came in at $0.71 surpassing the estimated $0.57 by +24.56%, while revenue for the quarter reached $381.27m , missing expectations by -1.88%.
Earnings released on 26 Apr 2023
EPS came in at $0.74 matching the estimated $0.74, while revenue for the quarter reached $380.85m , beating expectations by +2.05%.
Earnings released on 22 Feb 2023
EPS came in at $0.94 surpassing the estimated $0.93 by +1.08%, while revenue for the quarter reached $398.02m , beating expectations by +0.02%.
Earnings released on 26 Oct 2022
EPS came in at $0.86 surpassing the estimated $0.72 by +19.44%, while revenue for the quarter reached $385.19m , beating expectations by +1.81%.
Earnings released on 27 Jul 2022
EPS came in at $0.82 surpassing the estimated $0.80 by +2.50%, while revenue for the quarter reached $397.82m , beating expectations by +0.62%.
Earnings released on 27 Apr 2022
EPS came in at $0.74 surpassing the estimated $0.68 by +8.82%, while revenue for the quarter reached $376.64m , beating expectations by +3.93%.
Earnings released on 23 Feb 2022
EPS came in at $0.84 surpassing the estimated $0.83 by +1.20%, while revenue for the quarter reached $405.52m , beating expectations by +0.24%.
Earnings released on 2 Nov 2021
EPS came in at $0.86 surpassing the estimated $0.72 by +19.44%, while revenue for the quarter reached $386.86m , beating expectations by +0.34%.
Earnings released on 28 Jul 2021
EPS came in at $0.79 surpassing the estimated $0.67 by +17.91%, while revenue for the quarter reached $389.99m , beating expectations by +1.15%.
IART Stock Performance
Access detailed IART performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
